Medicare GLP-1 Bridge Coverage 2026: What Cash-Pay Patients Should Know

Starting July 1, 2026, eligible Medicare Part D beneficiaries can access select GLP-1 obesity medications through the Medicare GLP-1 Bridge for $50 per month. CMS says the program runs through December 31, 2027. It is not ordinary Part D coverage, and it does not automatically solve access for every cash-pay patient.

The practical answer: if you are on Medicare Part D and meet the Bridge criteria, this could be the lowest legal cash price for covered brand-name GLP-1 obesity treatment. If you are not eligible, or if you use a drug or formulation outside the Bridge, you still need to compare manufacturer cash-pay programs, insurance-covered indications, and reputable telehealth options.

Quick Answer: What Changed

This is a bridge program, not a permanent Medicare obesity-drug benefit. That distinction matters because access after 2027 is still uncertain.

What the Medicare GLP-1 Bridge Is

CMS describes the Medicare GLP-1 Bridge as a short-term demonstration for eligible Medicare Part D beneficiaries. It is separate from the BALANCE Model, which was designed to expand access to GLP-1 medications and lifestyle interventions for Medicare and Medicaid populations.

The key dates are now clear. CMS says the Bridge will provide access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. KFF notes that the program was originally expected to run only from July through December 2026, then was extended through the end of 2027 after Medicare Part D implementation of BALANCE was delayed.

The Bridge also uses a different payment structure from standard Part D. CMS says Part D sponsors do not carry risk for eligible GLP-1 drugs furnished under the Bridge, and plans do not have to opt in for eligible beneficiaries to access covered drugs. In 2026, CMS plans to use a central processor for prior authorization, claims adjudication, and pharmacy payment.

Who May Be Eligible

The Bridge is for Medicare beneficiaries enrolled in Part D plans who meet CMS eligibility criteria and receive a prior authorization submitted by their provider. KFF summarizes the process this way: the provider must attest that the drug is being prescribed to reduce excess body weight and maintain weight reduction, and that the beneficiary fits one of the BMI and clinical-diagnostic categories CMS uses for the program.

That means eligibility is not just, "I want Wegovy." You should expect documentation and prior authorization.

Also important: if you already receive a GLP-1 through Part D for a Medicare-covered indication, such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea, KFF says you continue through your Part D plan rather than the Bridge. The Bridge is specifically for obesity use.

Which Drugs Are Included

CMS currently lists these eligible GLP-1 drugs for weight reduction under the Bridge:

• Foundayo
• Wegovy injection and tablets
• Zepbound KwikPen

CMS notes that the list was updated to include Foundayo after FDA approval and to clarify that only the KwikPen formulation of Zepbound is included. That formulation detail matters. If you are comparing Zepbound cash-pay vials, pens, or KwikPen access, do not assume every product presentation is treated the same way.

The covered-drug list can change, so verify the current CMS page before making a decision.

What It Costs Compared With Cash-Pay Options

The headline number is simple: $50 per month for eligible Bridge fills. KFF reports manufacturers agreed to provide eligible GLP-1s under the Bridge at a $245 net price per monthly supply, with pharmacies collecting the $50 copay and CMS handling the demonstration payment flow.

For cash-pay patients, that is far below most current alternatives.

The Bridge is the clear price winner if you qualify. But if you do not qualify, brand direct programs and reputable telehealth programs are still the comparison set.

See PeptidePub's provider comparison, cheapest semaglutide guide, and compounded tirzepatide cost guide for cash-pay options.

What Is Still Not Covered

The Bridge does not erase the old Medicare rule overnight. KFF explains that current law generally prohibits Medicare Part D from covering medications when used specifically for weight loss. Medicare can cover GLP-1s for other medically accepted FDA-approved uses, such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea.

The Bridge is a temporary demonstration that creates a separate path for obesity use. It is not the same thing as permanent nationwide Part D obesity-drug coverage.

It also does not solve every access problem:

• The $50 copay may still be too much for some low-income beneficiaries, and KFF reports Low-Income Subsidy cost-sharing subsidies do not apply inside the Bridge.
• The $50 does not count toward the Part D deductible or out-of-pocket maximum, according to KFF.
• Access after December 31, 2027 is uncertain.
• Prior authorization can still block or delay use.
• Drugs or formulations outside the CMS list may not qualify.

How BALANCE Fits In

BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. CMS says the model aims to increase access to selected GLP-1 medications and healthy lifestyle interventions for people with Medicare and Medicaid.

The Medicare side has been delayed. KFF reports that CMS announced it would not move forward with Medicare Part D BALANCE implementation in 2027 and would extend the Bridge through the end of 2027 instead. CMS cited the need for more GLP-1 utilization data and a smoother transition.

The Medicaid side is different. CMS says state Medicaid agencies can join BALANCE beginning in May 2026 through January 1, 2027, and KFF reports Medicaid BALANCE plans were not affected by the Medicare delay.

For patients, the takeaway is simple: Bridge first, possible BALANCE transition later, but no guaranteed permanent Medicare obesity coverage after 2027 yet.

Why Medicare Is Moving Now: The Evidence

GLP-1 obesity drugs are expensive, but they are not marginal treatments. The evidence base is why CMS is testing broader access.

In STEP 1, Wilding and colleagues reported in the New England Journal of Medicine in 2021 that once-weekly semaglutide 2.4 mg produced 14.9% average weight loss at 68 weeks in 1,961 adults with overweight or obesity, compared with 2.4% with placebo.

In SURMOUNT-1, Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that tirzepatide produced large weight reductions over 72 weeks in 2,539 adults with obesity or overweight. Eli Lilly's summary of the published trial reported 16.0% to 22.5% average weight loss across doses, with up to 39.7% of participants on 15 mg achieving at least 25% body-weight reduction.

In SELECT, Lincoff and colleagues reported in the New England Journal of Medicine in 2023 that semaglutide reduced major adverse cardiovascular events by 20% in 17,604 adults with established cardiovascular disease and BMI of at least 27, without diabetes. That trial helped move Wegovy beyond a weight-only conversation.

None of this means everyone should take a GLP-1. It does explain why CMS is testing access despite the budget pressure.

What Cash-Pay Patients Should Do Next

If you are on Medicare Part D, ask three questions before July 2026:

1. Do I meet the BMI and clinical criteria for the Bridge?
2. Is my prescribed drug and formulation on the CMS list?
3. What documentation will my clinician need for prior authorization?

If you are not eligible for the Bridge, compare your real alternatives instead of assuming cash-pay means one price category.

• Check manufacturer direct pricing for Wegovy or Zepbound.
• Verify whether you have coverage for diabetes, cardiovascular risk reduction, or sleep apnea indications.
• Compare reputable telehealth programs if you are considering compounded options.
• Avoid sellers that do not require a prescription or market research chemicals for self-treatment.

Bottom Line

The Medicare GLP-1 Bridge could make covered obesity GLP-1 treatment dramatically cheaper for eligible Part D beneficiaries from July 1, 2026 through December 31, 2027. The key number is $50 per month. The key caveat is that this is temporary, criteria-based, and separate from ordinary Part D coverage.

If you qualify, talk with your clinician about the prior authorization process. If you do not qualify, compare current manufacturer self-pay pricing and reputable telehealth options carefully. The right answer depends less on headlines and more on your eligibility, drug formulation, and total monthly cost.

Sources

• CMS: Medicare GLP-1 Bridge
• CMS: BALANCE Model
• CMS press release, May 6, 2026
• KFF: What to Know About BALANCE and the Medicare GLP-1 Bridge
• Wilding et al., New England Journal of Medicine, 2021: STEP 1 semaglutide obesity trial
• Jastreboff et al., New England Journal of Medicine, 2022: SURMOUNT-1 tirzepatide obesity trial
• Lincoff et al., New England Journal of Medicine, 2023: SELECT cardiovascular outcomes trial

FAQ

Does Medicare cover GLP-1 drugs for weight loss in 2026?

Standard Medicare Part D generally still does not cover drugs when used specifically for weight loss. The Medicare GLP-1 Bridge is a separate temporary demonstration that begins July 1, 2026 for eligible Part D beneficiaries.

How much will Medicare GLP-1 Bridge drugs cost?

CMS says eligible beneficiaries will pay $50 for a monthly supply through the Bridge.

Which GLP-1 drugs are included in the Medicare GLP-1 Bridge?

CMS currently lists Foundayo, Wegovy injection and tablets, and Zepbound KwikPen when used to reduce excess body weight and maintain weight reduction.

Does the $50 copay count toward the Part D out-of-pocket maximum?

KFF reports that the Bridge copay does not count toward the Part D deductible or the $2,100 out-of-pocket maximum in 2026.

What happens after the Bridge ends?

The Bridge is currently scheduled to end December 31, 2027. KFF notes that Medicare obesity-drug coverage after that date is uncertain unless CMS restarts, restructures, or replaces the delayed Medicare BALANCE pathway.